Stay updated with breaking news from Enveric Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reissued their buy rating on shares of Enveric Biosciences (NASDAQ:ENVB – Free Report) in a research note issued to investors on Tuesday, Marketbeat reports. The firm currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Enveric Biosciences’ Q4 2023 earnings at ($1.50) EPS, FY2023 earnings at ($8.10) […]
The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder.
Enveric Bioscience CEO Dr. Joseph Tucker joined Steve Darling from Proactive to share news about the company that is looking to help with the opioid crisis...
23.03.2023 - Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that ... Seite 1
Psychedelic drugs and therapy are fueling the conversations on potentially revolutionary treatment and a paradigm shift for mental health disorders.